Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07722754 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial

Study acronym: BOND-4
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description shortened, about 4 words
  2. Recruitment opened Show 6 more changesShow less
    • Lead sponsor: Guangdong Provincial People's Hospital to Guangdong Provincial People's Hospital
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 1, 2026 to Jul 23, 2026
    • Eligibility criteria expanded, about 28 words
    • Study description shortened, about 7 words
    • Publications: details revised at 1 of 1 entry
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Primary endpoint: objective response rate Secondary endpoints: progression-free survival (PFS), overall survival (OS) and adverse events.
Trial Details
NCT Number NCT07722754
Lead Sponsor Guangdong Provincial People's Hospital
Conditions
(from sponsor)		 Colorectal Neoplasms Malignant, Neoplasm, Metastatic
Related terms Colonic Neoplasms, Neoplasm Metastasis
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov